April 07, 2026 a 07:43 am
SYK: Fundamental Ratio Analysis - Stryker Corporation
Stryker Corporation, a leader in the medical technology field, shows strong market positions across various segments like Orthopaedics and Neurotechnology. Its innovative product range and global reach shine as competitive advantages, though its valuation metrics indicate certain risks. This makes it an intriguing watch for growth-focused investors.
Fundamental Rating (H2)
Stryker Corporation's fundamental scores suggest stability with room for improvement, especially in areas like debt management and valuation metrics.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 4 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
The historical data provides a perspective of stability over time, though the overall score has seen slight changes indicative of market shifts.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-04-06 | 3 | 4 | 4 | 5 | 1 | 1 | 1 |
| Previous Date | 0 | 4 | 4 | 5 | 1 | 1 | 1 |
Analyst Price Targets
The analyst price targets provide a wide range, suggesting differing opinions on valuation, with a general consensus pointing upwards.
| High | Low | Median | Consensus |
|---|---|---|---|
| 469 | 390 | 426.5 | 428.67 |
Analyst Sentiment
The current analyst sentiment is positive, with a strong buy inclination overwhelmingly supported by a significant number of analysts.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 35 | |
| Hold | 14 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Stryker Corporation presents a mix of promising growth prospects and current valuation challenges. Its leadership in medical technology and diversification across segments offers significant competitive advantages. However, the stock's valuation metrics suggest prudent financial management is critical, with a focus on debt and earnings. Analysts remain optimistic, evident from the upward consensus on price targets and buy ratings, indicating a potential for growth if macroeconomic conditions remain favorable.